Market Overview:
The Global Systemic Candidiasis Market is expected to grow at a CAGR of XX% from 2018 to 2030. The market growth factors include the increasing incidence of fungal infections, rising demand for better treatment options, and the growing awareness about fungal infections. The market is segmented by type into systemic oral azoles, voriconazole, liposomal amphotericin B, and topical antifungal agents. The systemic oral azoles segment is expected to grow at the highest CAGR during the forecast period owing to their high efficacy and safety profile. By application, the hospital segment dominates the global systemic candidiasis market due to increased prevalence of fungal infections in hospitalized patients. However, with increasing demand for better treatment options and growing awareness about fungal infections among patients outside hospitals settings such as clinics and home care settings; other segments such as clinics are projected to witness higher growth rates during the forecast period.
Product Definition:
Systemic candidiasis is a fungal infection that affects organs throughout the body. It can cause serious health problems, including death.
Systemic Oral Azoles:
Systemic oral azoles is a group of anti-fungal medication primarily used for the treatment of systemic fungal infections. The drug works by targeting the fungal cell wall and inhibiting its growth. Some of the commonly prescribed medications in this category are Noxafil, Vfend, Diflucan, and Cresemba.
Voriconazole:
Voriconazole is an antifungal medication primarily used to treat systemic fungal infections. It works by targeting the fungal cell wall and inhibiting its biosynthesis. The drug was first developed in the early 1980s as a topical preparation for the treatment of onychomycosis, a disease mainly affecting the nails.
Application Insights:
Based on application, the global systemic candidiasis market is segmented into hospital, clinic and others. The other applications include ICU settings and emergency rooms. In 2017, the hospital accounted for the largest share in terms of revenue as well as volume. This can be attributed to factors such as availability of resources such as personnel with expertise in diagnosis and treatment of fungal infections along with advanced diagnostic facilities that enable quick detection of infection at its early stages which further aids efficient management.
The others segment includes surgical clinics or hospitals that are not equipped with an intensive care unit (ICU) but have a high number of patients suffering from severe systemic fungal infections (SFIs). These settings primarily treat chronic diseases where there is a need to manage multiple antifungal resistant bacteria simultaneously thereby increasing utilization rates thus driving growth over the forecast period.
Regional Analysis:
Europe was the largest regional market in 2017 owing to the high prevalence of CD and increasing adoption of systemic antifungal drugs. In addition, growing awareness aboutCandida infections among people is expected to drive regional market growth over the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing regions during the forecast years due to rising healthcare expenditure, improving access to healthcare facilities and an increase in patient pool in this region. Moreover, increasing incidence rate of HIV/AIDS has increased susceptibility towards yeast-related infections such as Candidiasis among patients which will further boost market growth over projected period. Increasing number of product launches coupled with high unmet needs for treatment are some other factors driving this regional market at a significant pace during forecast years.
Growth Factors:
- Increasing incidence of systemic candidiasis due to increasing number of patients suffering from immunocompromised conditions such as AIDS, cancer, and diabetes.
- Growing awareness about the symptoms and diagnosis of systemic candidiasis among physicians and patients alike.
- Development of new antifungal drugs that are more effective against systemic candidiasis infections.
- Emergence of novel diagnostic techniques for detecting early-stage systemic candidiasis infections.
Scope Of The Report
Report Attributes
Report Details
Report Title
Systemic Candidiasis Market Research Report
By Type
Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Others
By Application
Hospital, Clinic, Others
By Companies
Novartis Ag, Sanofi-Aventis, Pfizer, Inc., Merck And Co., Inc., Enzon Pharmaceuticals Inc., Bayer Ag, Astellas Pharma, Inc., Glaxosmithkline Plc, Abbott, Cipla
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
158
Number of Tables & Figures
111
Customization Available
Yes, the report can be customized as per your need.
Global Systemic Candidiasis Market Report Segments:
The global Systemic Candidiasis market is segmented on the basis of:
Types
Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis Ag
- Sanofi-Aventis
- Pfizer, Inc.
- Merck And Co., Inc.
- Enzon Pharmaceuticals Inc.
- Bayer Ag
- Astellas Pharma, Inc.
- Glaxosmithkline Plc
- Abbott
- Cipla
Highlights of The Systemic Candidiasis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Systemic Oral Azoles
- Voriconazole
- Liposomal Amphotericin B
- Topical Antifungal Agents
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Candidiasis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Systemic candidiasis is an infection of the entire body caused by Candida albicans. Systemic candidiasis can occur in people of any age, but is most common in adults over 50 years old. Systemic candidiasis can cause a wide range of symptoms, including:nnfevernheadachennausea and vomitingnmuscle aches and pain
Some of the major players in the systemic candidiasis market are Novartis Ag, Sanofi-Aventis, Pfizer, Inc., Merck And Co., Inc., Enzon Pharmaceuticals Inc., Bayer Ag, Astellas Pharma, Inc., Glaxosmithkline Plc, Abbott, Cipla.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Systemic Candidiasis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Systemic Candidiasis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Systemic Candidiasis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Systemic Candidiasis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Systemic Candidiasis Market Size & Forecast, 2018-2028
4.5.1 Systemic Candidiasis Market Size and Y-o-Y Growth
4.5.2 Systemic Candidiasis Market Absolute $ Opportunity
Chapter 5 Global Systemic Candidiasis Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Systemic Candidiasis Market Size Forecast by Type
5.2.1 Systemic Oral Azoles
5.2.2 Voriconazole
5.2.3 Liposomal Amphotericin B
5.2.4 Topical Antifungal Agents
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Systemic Candidiasis Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Systemic Candidiasis Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Systemic Candidiasis Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Systemic Candidiasis Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Systemic Candidiasis Analysis and Forecast
9.1 Introduction
9.2 North America Systemic Candidiasis Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Systemic Candidiasis Market Size Forecast by Type
9.6.1 Systemic Oral Azoles
9.6.2 Voriconazole
9.6.3 Liposomal Amphotericin B
9.6.4 Topical Antifungal Agents
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Systemic Candidiasis Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Systemic Candidiasis Analysis and Forecast
10.1 Introduction
10.2 Europe Systemic Candidiasis Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Systemic Candidiasis Market Size Forecast by Type
10.6.1 Systemic Oral Azoles
10.6.2 Voriconazole
10.6.3 Liposomal Amphotericin B
10.6.4 Topical Antifungal Agents
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Systemic Candidiasis Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Systemic Candidiasis Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Systemic Candidiasis Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Systemic Candidiasis Market Size Forecast by Type
11.6.1 Systemic Oral Azoles
11.6.2 Voriconazole
11.6.3 Liposomal Amphotericin B
11.6.4 Topical Antifungal Agents
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Systemic Candidiasis Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Systemic Candidiasis Analysis and Forecast
12.1 Introduction
12.2 Latin America Systemic Candidiasis Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Systemic Candidiasis Market Size Forecast by Type
12.6.1 Systemic Oral Azoles
12.6.2 Voriconazole
12.6.3 Liposomal Amphotericin B
12.6.4 Topical Antifungal Agents
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Systemic Candidiasis Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Systemic Candidiasis Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Systemic Candidiasis Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Systemic Candidiasis Market Size Forecast by Type
13.6.1 Systemic Oral Azoles
13.6.2 Voriconazole
13.6.3 Liposomal Amphotericin B
13.6.4 Topical Antifungal Agents
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Systemic Candidiasis Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Systemic Candidiasis Market: Competitive Dashboard
14.2 Global Systemic Candidiasis Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis Ag
14.3.2 Sanofi-Aventis
14.3.3 Pfizer, Inc.
14.3.4 Merck And Co., Inc.
14.3.5 Enzon Pharmaceuticals Inc.
14.3.6 Bayer Ag
14.3.7 Astellas Pharma, Inc.
14.3.8 Glaxosmithkline Plc
14.3.9 Abbott
14.3.10 Cipla
